Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 19, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 370,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,339.71 pence per share.
- Treasury Holdings: 106,248,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,837,949,999 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares due to the repurchase of 370,000 shares on August 19, 2005. These shares are intended to be held in Treasury. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 370,000 share repurchase based on the disclosed price of 1,339.71 pence per share.
- Confirm the updated total share capital structure (5,837,949,999 shares in issue plus 106,248,000 Treasury shares).
- Review the original shareholder resolution from the May 25, 2005 Annual General Meeting to confirm the remaining authorization for future buybacks.